Papers/PMID:39533603
Meta-analysis of the efficacy and impact on cardiac function of sodium-glucose cotransporter 2 inhibitor Empagliflozin in heart failure patients.
Medicine2024The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
empagliflozin — decreases cardiovascular mortality
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×1“The results indicated that Empagliflozin group exhibited a lower cardiovascular disease mortality rate versus Ctrl group (OR = 0.89, 95% CI: 0.82 to 0.97, Z = 2.73, P =.006), while neglectable difference existed in the all-cause mortality rate versus Ctrl group (OR = 0.92, 95% CI: 0.84 to 1.01, Z = 1.72, P =.09).”
Quoted verbatim from Meta-analysis of the efficacy and impact on cardiac function of sodium-glucose cotransporter 2 inhibitor Empagliflozin in heart failure patients.. - Study
- meta-analysis
- Dose
- 10 mg
- Population
- Patients with heart failure of any type; 15 pooled RCTs, empagliflozin 10 mg versus placebo (control group)
Effect 0.89 odds ratio, 95% CI 0.82 to 0.97
Meta-analysis of the efficacy and impact on cardiac function of sodium-glucose cotransporter 2 inhibitor Empagliflozin in heart failure patients.2024PMID:39533603Permalink